Viewpoints

Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.

Industry's focus on cost cutting has led to a dangerous gap in training and knowledge.

Cases of overlooking proper packaging, reconstitution, directions, and dissolution.

Industry can meet its responsibility to society by considering innovative pricing and partnerships.

Three therapies under review could help Americans attain a healthy weight.

With more hands in the manufacturing pot, a good contingency plan is crucial to success.

Duke University researchers have found a possible alternative to lyophilization.

To continue innovating, the biopharmaceutical sector needs support from all levels.

Reports of overlooked controls, dropped pallets, and misplaced documents leave a chill in the air.

After a spate of industrial disasters, the public seeks greater oversight of corporations-so does FDA.

We decided to dedicate this month's issue of PTE to a topic that affects all of our readers; the threat of counterfeit medicines.

Too much or too little control can actually lead to the same result.

Have you ever come across a new technology, process or problem in your profession and wanted to tell others or learn more about it?

FDA wants industry to talk to them about the science underlying process innovations-really.

A Pharma Business Imperative.

Agreement on standards for excipient qualification, development, and fair pricing is underway.

When vessels, seals, and cooling units go haywire, operators must get in the mix.

Over the last few months, we have been publishing a series of special features, which have sought to provide you with an overall view of current challenges, innovations and trends in niche pockets of the pharmaceutical industry.

As the industry continues to evolve, do we know where we're headed?

Laboratory personnel share interesting tales as well as stories of unexpected tails.

The BIO convention, and healthcare reform, could re-energize biotech.

Change is a part of life which some fear whilst others thrive. In the commercial world, a fundamental aspect of good management is to apply strategic insight to react to change in order to survive and grow. The pharmaceutical industry, as with every industry, is constantly exposed to new threats. Companies are all too painfully aware that the external threats that it currently faces, as well as the threat of their own drying pipelines, are forcing it to adapt and to stay on the lookout for new opportunities - now more than ever.

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Contract manufacturers report improving business conditions, but will they continue?

From last-minute product inserts to putting out fires, close calls are a common occurrence.

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

Last year, a member of the PTE editorial team attended the 2nd Annual Lyophilisation Conference in London (UK).

Sharing too much-or too little-information can have disastrous onsequences.

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

When it comes to healthcare rform, we must not overlook investment in innovative technologies.